In a heterogeneous disease such as multiple myeloma, data generation, sharing and analysis coupled with broad collaboration are essential tools to speed progress. Robust efforts are needed to build bridges, foster cooperation and share ideas between the pharmaceutical industry, academic research centers and community oncologists. It is only by working together that we can aggregate enough data to do meaningful analysis – especially when studying many different multiple myeloma subtypes. No single organization can do it alone.
The Multiple Myeloma Research Foundation (MMRF) CoMMpass Study℠ Data Jamboree 2016 exemplifies this approach. Held in Cambridge, Massachusetts, the MMRF invited over 40 attendees from various nonprofit, academic and pharmaceutical organizations to discuss new findings and next steps related to the landmark CoMMpass Study℠, an initiative which is changing how researchers think about using data to drive actionable insights in the clinic.
CoMMpass, the cornerstone of the MMRF’s Precision Medicine Initiative, is a prospective, longitudinal, observational study capturing the largest genomic data set in multiple myeloma. This study follows 1,000 patients throughout the course of their disease. By mapping each patient’s genomic profiles to clinical outcomes, CoMMpass is enabling precision medicine in multiple myeloma patients – delivering the right treatment at the right time.
CoMMpass is the largest, deepest, most robust data set in the field of multiple myeloma.
Representatives from CoMMpass’ participating organizations regularly meet to review the maturing data, explore trends and consider new hypotheses. Preliminary findings from CoMMpass have already provided insight into clinical questions of great importance to patients – Should I be on triplet or doublet-based initial therapy? Should I have a stem cell transplant? Is my genomic profile predicitive?
Participants in the CoMMpass Data Jamboree 2016 discussed recent findings to further understand the characteristics of newly diagnosed patients with multiple myeloma. Future questions that we need to address include better ways to measure response to treatment, predictors of response and drug-related toxicities. We also need to develop the most appropriate molecular tests and study the potential role of immune system in treating multiple myeloma.
Moving forward, the MMRF and CoMMpass stakeholders are committed to continued collaboration, data sharing and the use of broad, cutting-edge technology in order to advance precision medicine – with the ultimate goal of improving the lives of patients with multiple myeloma.